{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:05:25Z","timestamp":1789790725284,"version":"4.0.1"},"reference-count":75,"publisher":"Tohoku University Medical Press","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.1620\/tjem.2026.j082","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:10:36Z","timestamp":1784153436000},"page":"437-447","source":"Crossref","is-referenced-by-count":0,"title":["Cracking a New Era of Therapeutic Development in ALS"],"prefix":"10.1620","volume":"269","author":[{"given":"Tetsuya","family":"Akiyama","sequence":"first","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., Takahashi, F., Kondo, K., Yoshino, H.; Edaravone (MCI-186) ALS 19 Study Group(2017a) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Neurology<\/i>, 16, 505-512. https:\/\/doi.org\/10.1016\/S1474-4422(17)30115-1","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"2","doi-asserted-by":"publisher","unstructured":"Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., Hamada, C., Tanaka, M., Akimoto, M., Nakamura, K., Takahashi, F., Kondo, K., Yoshino, H.; Edaravone (MCI-186) ALS 19 Study Group(2017b) Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. <i>Amyotroph. Lateral Scler. Frontotemporal. Degener.<\/i>, 18, 55-63. https:\/\/doi.org\/10.1080\/21678421.2017.1364269","DOI":"10.1080\/21678421.2017.1364269"},{"key":"3","doi-asserted-by":"publisher","unstructured":"Abe, K., Itoyama, Y., Sobue, G., Tsuji, S., Aoki, M., Doyu, M., Hamada, C., Kondo, K., Yoneoka, T., Akimoto, M., Yoshino, H.&amp;Edaravone, A.L.S.S.G. (2014)  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. <i>Amyotroph. Lateral Scler. Frontotemporal. Degener.<\/i>, 15, 610-617. https:\/\/doi.org\/10.3109\/21678421.2014.959024","DOI":"10.3109\/21678421.2014.959024"},{"key":"4","doi-asserted-by":"publisher","unstructured":"Akiyama, T., Koike, Y., Petrucelli, L.&amp;Gitler, A.D. (2022)  Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers. <i>Clin. Transl. Med.<\/i>, 12, e818. https:\/\/doi.org\/10.1002\/ctm2.818","DOI":"10.1002\/ctm2.818"},{"key":"5","doi-asserted-by":"publisher","unstructured":"Akiyama, T., Suzuki, N., Ishikawa, M., Fujimori, K., Sone, T., Kawada, J., Funayama, R., Fujishima, F., Mitsuzawa, S., Ikeda, K., Ono, H., Shijo, T., Osana, S., Shirota, M., Nakagawa, T., et al. (2019)  Aberrant axon branching via Fos-B dysregulation in FUS-ALS motor neurons. <i>EBioMedicine<\/i>, 45, 362-378. https:\/\/doi.org\/10.1016\/j.ebiom.2019.06.013","DOI":"10.1016\/j.ebiom.2019.06.013"},{"key":"6","doi-asserted-by":"publisher","unstructured":"Akiyama, T., Warita, H., Kato, M., Nishiyama, A., Izumi, R., Ikeda, C., Kamada, M., Suzuki, N.&amp;Aoki, M. (2016)  Genotype-phenotype relationships in familial amyotrophic lateral sclerosis with FUS\/TLS mutations in Japan. <i>Muscle Nerve<\/i>, 54, 398-404. https:\/\/doi.org\/10.1002\/mus.25061","DOI":"10.1002\/mus.25061"},{"key":"7","doi-asserted-by":"publisher","unstructured":"Andrews, J., Paganoni, S., Macklin, E.A., Chibnik, L.B., Quintana, M., Saville, B.R., Detry, M.A., Vestrucci, M., Marion, J., McGlothlin, A., Young, E., Chase, M., Pothier, L., Harkey, B., Yu, H., et al.; Writing Committee for the HEALEY ALS Platform Trial(2025)  Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. <i>JAMA Neurol<\/i>, 82, 333-343. https:\/\/doi.org\/10.1001\/jamaneurol.2024.5249","DOI":"10.1001\/jamaneurol.2024.5249"},{"key":"8","doi-asserted-by":"publisher","unstructured":"Aoki, M., Ogasawara, M., Matsubara, Y., Narisawa, K., Nakamura, S., Itoyama, Y.&amp;Abe, K. (1993)  Mild ALS in Japan associated with novel SOD mutation. <i>Nat. Genet.<\/i>, 5, 323-324. https:\/\/doi.org\/10.1038\/ng1293-323","DOI":"10.1038\/ng1293-323"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., Mann, D., Tsuchiya, K., Yoshida, M., Hashizume, Y.&amp;Oda, T. (2006)  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Biochem. Biophys. Res. Commun.<\/i>, 351, 602-611. https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.093","DOI":"10.1016\/j.bbrc.2006.10.093"},{"key":"10","doi-asserted-by":"publisher","unstructured":"Baughn, M.W., Melamed, Z., Lopez-Erauskin, J., Beccari, M.S., Ling, K., Zuberi, A., Presa, M., Gonzalo-Gil, E., Maimon, R., Vazquez-Sanchez, S., Chaturvedi, S., Bravo-Hernandez, M., Taupin, V., Moore, S., Artates, J.W., et al. (2023)  Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies. <i>Science<\/i>, 379, 1140-1149. https:\/\/doi.org\/10.1126\/science.abq5622","DOI":"10.1126\/science.abq5622"},{"key":"11","doi-asserted-by":"publisher","unstructured":"Becker, L.A., Huang, B., Bieri, G., Ma, R., Knowles, D.A., Jafar-Nejad, P., Messing, J., Kim, H.J., Soriano, A., Auburger, G., Pulst, S.M., Taylor, J.P., Rigo, F.&amp;Gitler, A.D. (2017)  Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. <i>Nature<\/i>, 544, 367-371. https:\/\/doi.org\/10.1038\/nature22038","DOI":"10.1038\/nature22038"},{"key":"12","doi-asserted-by":"publisher","unstructured":"Benatar, M.(2007)  Lost in translation: treatment trials in the SOD1 mouse and in human ALS. <i>Neurobiol. Dis.<\/i>, 26, 1-13. https:\/\/doi.org\/10.1016\/j.nbd.2006.12.015","DOI":"10.1016\/j.nbd.2006.12.015"},{"key":"13","doi-asserted-by":"publisher","unstructured":"Benatar, M., Wuu, J., Andersen, P.M., Bucelli, R.C., Andrews, J.A., Otto, M., Farahany, N.A., Harrington, E.A., Chen, W., Mitchell, A.A., Ferguson, T., Chew, S., Gedney, L., Oakley, S., Heo, J., et al. (2022)  Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. <i>Neurotherapeutics<\/i>, 19, 1248-1258. https:\/\/doi.org\/10.1007\/s13311-022-01237-4","DOI":"10.1007\/s13311-022-01237-4"},{"key":"14","doi-asserted-by":"publisher","unstructured":"Benatar, M., Wuu, J., Andersen, P.M., Lombardi, V.&amp;Malaspina, A. (2018)  Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. <i>Ann. Neurol.<\/i>, 84, 130-139. https:\/\/doi.org\/10.1002\/ana.25276","DOI":"10.1002\/ana.25276"},{"key":"15","doi-asserted-by":"publisher","unstructured":"Bilican, B., Serio, A., Barmada, S.J., Nishimura, A.L., Sullivan, G.J., Carrasco, M., Phatnani, H.P., Puddifoot, C.A., Story, D., Fletcher, J., Park, I.H., Friedman, B.A., Daley, G.Q., Wyllie, D.J., Hardingham, G.E., et al. (2012)  Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. <i>Proc. Natl. Acad. Sci. U. S. A.<\/i>, 109, 5803-5808. https:\/\/doi.org\/10.1073\/pnas.1202922109","DOI":"10.1073\/pnas.1202922109"},{"key":"16","doi-asserted-by":"publisher","unstructured":"Brown, A.L., Wilkins, O.G., Keuss, M.J., Kargbo-Hill, S.E., Zanovello, M., Lee, W.C., Bampton, A., Lee, F.C.Y., Masino, L., Qi, Y.A., Bryce-Smith, S., Gatt, A., Hallegger, M., Fagegaltier, D., Phatnani, H., et al. (2022)  TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. <i>Nature<\/i>, 603, 131-137. https:\/\/doi.org\/10.1038\/s41586-022-04436-3","DOI":"10.1038\/s41586-022-04436-3"},{"key":"17","doi-asserted-by":"publisher","unstructured":"Brown, R.H.&amp;Al-Chalabi, A. (2017)  Amyotrophic Lateral Sclerosis. <i>N. Engl. J. Med.<\/i>, 377, 162-172. https:\/\/doi.org\/10.1056\/NEJMra1603471","DOI":"10.1056\/NEJMra1603471"},{"key":"18","doi-asserted-by":"publisher","unstructured":"Chia, R., Chio, A.&amp;Traynor, B.J. (2018)  Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. <i>Lancet Neurol.<\/i>, 17, 94-102. https:\/\/doi.org\/10.1016\/S1474-4422(17)30401-5","DOI":"10.1016\/S1474-4422(17)30401-5"},{"key":"19","doi-asserted-by":"publisher","unstructured":"Copley, K.E., Mauna, J.C., Danielson, H.L., Chen, Q., Ozguney, B., Ngo, M., Xie, L., Smirnov, A., Davis, M., Mayne, L., Linsenmeier, M., Rubien, J.D., Bergmann, C.A., Portz, B., Lee, B.L., et al. (2026)  Short RNA chaperones promote aggregation-resistant TDP-43 conformers to mitigate neurodegeneration. <i>Science<\/i>, 392, eadv3301. https:\/\/doi.org\/10.1126\/science.adv3301","DOI":"10.1126\/science.adv3301"},{"key":"20","doi-asserted-by":"crossref","unstructured":"DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., Kouri, N., Wojtas, A., Sengdy, P., Hsiung, G.Y., Karydas, A., et al. (2011)  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. <i>Neuron<\/i>, 72, 245-256. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.011","DOI":"10.1016\/j.neuron.2011.09.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Dimos, J.T., Rodolfa, K.T., Niakan, K.K., Weisenthal, L.M., Mitsumoto, H., Chung, W., Croft, G.F., Saphier, G., Leibel, R., Goland, R., Wichterle, H., Henderson, C.E.&amp;Eggan, K. (2008)  Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. <i>Science<\/i>, 321, 1218-1221. https:\/\/doi.org\/10.1126\/science.1158799","DOI":"10.1126\/science.1158799"},{"key":"22","doi-asserted-by":"publisher","unstructured":"Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin, A.S., Johnson, B.S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M.M., Padmanabhan, A., Clay-Falcone, D., McCluskey, L., Elman, L., Juhr, D., et al. (2010)  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. <i>Nature<\/i>, 466, 1069-1075. https:\/\/doi.org\/10.1038\/nature09320","DOI":"10.1038\/nature09320"},{"key":"23","doi-asserted-by":"publisher","unstructured":"Feldman, E.L., Goutman, S.A., Petri, S., Mazzini, L., Savelieff, M.G., Shaw, P.J.&amp;Sobue, G. (2022)  Amyotrophic lateral sclerosis. <i>Lancet<\/i>, 400, 1363-1380. https:\/\/doi.org\/10.1016\/S0140-6736(22)01272-7","DOI":"10.1016\/S0140-6736(22)01272-7"},{"key":"24","doi-asserted-by":"publisher","unstructured":"Fujimori, K., Ishikawa, M., Otomo, A., Atsuta, N., Nakamura, R., Akiyama, T., Hadano, S., Aoki, M., Saya, H., Sobue, G.&amp;Okano, H. (2018)  Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. <i>Nat. Med.<\/i>, 24, 1579-1589. https:\/\/doi.org\/10.1038\/s41591-018-0140-5","DOI":"10.1038\/s41591-018-0140-5"},{"key":"25","doi-asserted-by":"publisher","unstructured":"Gendron, T.F.&amp;Petrucelli, L. (2018)  Disease Mechanisms of C9ORF72 Repeat Expansions. <i>Cold Spring Harb. Perspect. Med.<\/i>, 8, a024224. https:\/\/doi.org\/10.1101\/cshperspect.a024224","DOI":"10.1101\/cshperspect.a024224"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Gomberg, T.A., Elmsaouri, S., Kopalle, H.M., Baughn, M.W., Beccari, M.S., McAlonis-Downes, M., Artates, J.W., Pant, D., Mak, H., Smargon, A.A., Sander, T.C., Garcia, E., Lee, D.P., Cleveland, D.W.&amp;Yeo, G.W. (2025)  Dual-targeting snRNA gene therapy rescues STMN2 and UNC13A splicing in TDP-43 proteinopathies. bioRxiv. https:\/\/doi.org\/10.64898\/2025.12.01.691001[Epub ahead of print]","DOI":"10.64898\/2025.12.01.691001"},{"key":"27","doi-asserted-by":"publisher","unstructured":"Guo, C., Chen, K., Vatsavayai, S., Akiyama, T., Liu, C., Zeng, Y., Sianto, O., Yang, E., Bombosch, J., Powell, R., Zhen, S., Mekhoubad, S., Morrie, R.D., Miller, G., Ilic, D., et al. (2026)  Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction. <i>Sci. Transl. Med.<\/i>, 18, eaeb8517. https:\/\/doi.org\/10.1126\/scitranslmed.aeb8517","DOI":"10.1126\/scitranslmed.aeb8517"},{"key":"28","doi-asserted-by":"publisher","unstructured":"Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X.&amp; et al. (1994)  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. <i>Science<\/i>, 264, 1772-1775. https:\/\/doi.org\/10.1126\/science.8209258","DOI":"10.1126\/science.8209258"},{"key":"29","doi-asserted-by":"publisher","unstructured":"Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E.M., Logroscino, G., Robberecht, W., Shaw, P.J., Simmons, Z.&amp;van den Berg, L.H. (2017)  Amyotrophic lateral sclerosis. <i>Nat. Rev. Dis. Primers<\/i>, 3, 17085. https:\/\/doi.org\/10.1038\/nrdp.2017.85","DOI":"10.1038\/nrdp.2017.85"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Hosaka, T., Tsuji, H.&amp;Kwak, S. (2021)  RNA Editing: A New Therapeutic Target in Amyotrophic Lateral Sclerosis and Other Neurological Diseases. <i>Int. J. Mol. Sci.<\/i>, 22, 10958. https:\/\/doi.org\/10.3390\/ijms222010958","DOI":"10.3390\/ijms222010958"},{"key":"31","doi-asserted-by":"publisher","unstructured":"Hung, S.T., Linares, G.R., Chang, W.H., Eoh, Y., Krishnan, G., Mendonca, S., Hong, S., Shi, Y., Santana, M., Kueth, C., Macklin-Isquierdo, S., Perry, S., Duhaime, S., Maios, C., Chang, J., et al. (2023)  PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. <i>Cell<\/i>, 186, 786-802e728. https:\/\/doi.org\/10.1016\/j.cell.2023.01.005","DOI":"10.1016\/j.cell.2023.01.005"},{"key":"32","doi-asserted-by":"publisher","unstructured":"Imamura, K., Izumi, Y., Watanabe, A., Tsukita, K., Woltjen, K., Yamamoto, T., Hotta, A., Kondo, T., Kitaoka, S., Ohta, A., Tanaka, A., Watanabe, D., Morita, M., Takuma, H., Tamaoka, A., et al. (2017)  The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. <i>Sci. Transl. Med.<\/i>, 9, eaaf3962. https:\/\/doi.org\/10.1126\/scitranslmed.aaf3962","DOI":"10.1126\/scitranslmed.aaf3962"},{"key":"33","doi-asserted-by":"publisher","unstructured":"Irwin, K.E., Jasin, P., Braunstein, K.E., Sinha, I.R., Garret, M.A., Bowden, K.D., Chang, K., Troncoso, J.C., Moghekar, A., Oh, E.S., Raitcheva, D., Bartlett, D., Miller, T., Berry, J.D., Traynor, B.J., et al. (2024)  A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. <i>Nat. Med.<\/i>, 30, 382-393. https:\/\/doi.org\/10.1038\/s41591-023-02788-5","DOI":"10.1038\/s41591-023-02788-5"},{"key":"34","doi-asserted-by":"publisher","unstructured":"Ito, D.&amp;Okada, K. (2024)  Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis. <i>Ann. Clin. Transl. Neurol.<\/i>, 11, 3054-3063. https:\/\/doi.org\/10.1002\/acn3.52234","DOI":"10.1002\/acn3.52234"},{"key":"35","doi-asserted-by":"publisher","unstructured":"Joseph, B.J., Marshall, K.A., Harley, P., Mann, J.R., Alessandrini, F., Vanoye, C.G., Chi, W., Prudencio, M., Simkin, D., Kao, T.T., Desai, R.R., Keuss, M.J., Barattucci, S., Zanovello, M., Mehta, P.R., et al. (2025)  TDP-43-dependent mis-splicing of KCNQ2 triggers intrinsic neuronal hyperexcitability in ALS\/FTD. <i>Nat. Neurosci.<\/i>, 28, 2476-2492. https:\/\/doi.org\/10.1038\/s41593-025-02096-w","DOI":"10.1038\/s41593-025-02096-w"},{"key":"36","doi-asserted-by":"publisher","unstructured":"Kaji, R., Imai, T., Iwasaki, Y., Okamoto, K., Nakagawa, M., Ohashi, Y., Takase, T., Hanada, T., Shimizu, H., Tashiro, K.&amp;Kuzuhara, S. (2019)  Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II\/III randomised controlled study. <i>J. Neurol. Neurosurg. Psychiatry<\/i>, 90, 451-457. https:\/\/doi.org\/10.1136\/jnnp-2018-319294","DOI":"10.1136\/jnnp-2018-319294"},{"key":"37","doi-asserted-by":"publisher","unstructured":"Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X.R.&amp;Gitler, A.D. (2020)  ALS Genetics: Gains, Losses, and Implications for Future Therapies. <i>Neuron<\/i>, 108, 822-842. https:\/\/doi.org\/10.1016\/j.neuron.2020.08.022","DOI":"10.1016\/j.neuron.2020.08.022"},{"key":"38","doi-asserted-by":"publisher","unstructured":"Kim, G., Nakayama, L., Blum, J.A., Akiyama, T., Boeynaems, S., Chakraborty, M., Couthouis, J., Tassoni-Tsuchida, E., Rodriguez, C.M., Bassik, M.C.&amp;Gitler, A.D. (2022)  Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. <i>Cell Rep.<\/i>, 41, 111508. https:\/\/doi.org\/10.1016\/j.celrep.2022.111508","DOI":"10.1016\/j.celrep.2022.111508"},{"key":"39","doi-asserted-by":"publisher","unstructured":"Kiskinis, E., Sandoe, J., Williams, L.A., Boulting, G.L., Moccia, R., Wainger, B.J., Han, S., Peng, T., Thams, S., Mikkilineni, S., Mellin, C., Merkle, F.T., Davis-Dusenbery, B.N., Ziller, M., Oakley, D., et al. (2014)  Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. <i>Cell Stem Cell<\/i>, 14, 781-795. https:\/\/doi.org\/10.1016\/j.stem.2014.03.004","DOI":"10.1016\/j.stem.2014.03.004"},{"key":"40","doi-asserted-by":"publisher","unstructured":"Klim, J.R., Williams, L.A., Limone, F., Guerra San Juan, I., Davis-Dusenbery, B.N., Mordes, D.A., Burberry, A., Steinbaugh, M.J., Gamage, K.K., Kirchner, R., Moccia, R., Cassel, S.H., Chen, K., Wainger, B.J., Woolf, C.J., et al. (2019)  ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. <i>Nat. Neurosci.<\/i>, 22, 167-179. https:\/\/doi.org\/10.1038\/s41593-018-0300-4","DOI":"10.1038\/s41593-018-0300-4"},{"key":"41","doi-asserted-by":"publisher","unstructured":"Korben, V.A., Lyashchenko, A.K., Blanco-Redondo, B., Jafar-Nejad, P.&amp;Shneider, N.A. (2022)  Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. <i>Nat. Med.<\/i>, 28, 104-116. https:\/\/doi.org\/10.1038\/s41591-021-01615-z","DOI":"10.1038\/s41591-021-01615-z"},{"key":"42","doi-asserted-by":"publisher","unstructured":"Kwiatkowski, T.J. Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., Valdmanis, P., Rouleau, G.A., Hosler, B.A., Cortelli, P., de Jong, P.J., et al. (2009)  Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. <i>Science<\/i>, 323, 1205-1208. https:\/\/doi.org\/10.1126\/science.1166066","DOI":"10.1126\/science.1166066"},{"key":"43","doi-asserted-by":"publisher","unstructured":"Ling, S.C., Polymenidou, M.&amp;Cleveland, D.W. (2013)  Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. <i>Neuron<\/i>, 79, 416-438. https:\/\/doi.org\/10.1016\/j.neuron.2013.07.033","DOI":"10.1016\/j.neuron.2013.07.033"},{"key":"44","doi-asserted-by":"publisher","unstructured":"Ludolph, A.C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J.P., Mead, R., Niessen, H.G., Petri, S., Pradat, P.F., Robberecht, W., Ruegg, M., Schwalenstocker, B., Stiller, D., van den Berg, L., et al. (2010)  Guidelines for preclinical animal research in ALS\/MND: A consensus meeting. <i>Amyotroph. Lateral Scler.<\/i>, 11, 38-45. https:\/\/doi.org\/10.3109\/17482960903545334","DOI":"10.3109\/17482960903545334"},{"key":"45","doi-asserted-by":"publisher","unstructured":"Ma, X.R., Prudencio, M., Koike, Y., Vatsavayai, S.C., Kim, G., Harbinski, F., Briner, A., Rodriguez, C.M., Guo, C., Akiyama, T., Schmidt, H.B., Cummings, B.B., Wyatt, D.W., Kurylo, K., Miller, G., et al. (2022)  TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. <i>Nature<\/i>, 603, 124-130. https:\/\/doi.org\/10.1038\/s41586-022-04424-7","DOI":"10.1038\/s41586-022-04424-7"},{"key":"46","doi-asserted-by":"publisher","unstructured":"Matharu, N., Rattanasopha, S., Tamura, S., Maliskova, L., Wang, Y., Bernard, A., Hardin, A., Eckalbar, W.L., Vaisse, C.&amp;Ahituv, N. (2019)  CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. <i>Science<\/i>, 363, eaau0629. https:\/\/doi.org\/10.1126\/science.aau0629","DOI":"10.1126\/science.aau0629"},{"key":"47","doi-asserted-by":"publisher","unstructured":"Melamed, Z., Lopez-Erauskin, J., Baughn, M.W., Zhang, O., Drenner, K., Sun, Y., Freyermuth, F., McMahon, M.A., Beccari, M.S., Artates, J.W., Ohkubo, T., Rodriguez, M., Lin, N., Wu, D., Bennett, C.F., et al. (2019)  Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. <i>Nat. Neurosci.<\/i>, 22, 180-190. https:\/\/doi.org\/10.1038\/s41593-018-0293-z","DOI":"10.1038\/s41593-018-0293-z"},{"key":"48","doi-asserted-by":"publisher","unstructured":"Miller, T.M., Cudkowicz, M.E., Genge, A., Shaw, P.J., Sobue, G., Bucelli, R.C., Chi\u00f2, A., Damme, P.V., Ludolph, A.C., Glass, J.D., Andrews, J.A., Babu, S., Benatar, M., McDermott, C.J., Cochrane, T., et al. (2022)  Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. <i>New England Journal of Medicine<\/i>, 387, 1099-1110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","DOI":"10.1056\/NEJMoa2204705"},{"key":"49","doi-asserted-by":"publisher","unstructured":"Miller, T.M., Cudkowicz, M.E., Shaw, P.J., Genge, A., Sobue, G., Bucelli, R.C., Chio, A., Van Damme, P., Ludolph, A.C., Glass, J.D., Andrews, J.A., Babu, S., Benatar, M., McDermott, C.J., Salachas, F., et al. (2026)  Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. <i>JAMA Neurol.<\/i>, 83, 115-125. https:\/\/doi.org\/10.1001\/jamaneurol.2025.4946","DOI":"10.1001\/jamaneurol.2025.4946"},{"key":"50","doi-asserted-by":"publisher","unstructured":"Mitsuzawa, S., Suzuki, N., Akiyama, T., Ishikawa, M., Sone, T., Kawada, J., Funayama, R., Shirota, M., Mitsuhashi, H., Morimoto, S., Ikeda, K., Shijo, T., Ohno, A., Nakamura, N., Ono, H., et al. (2021)  Reduced PHOX2B stability causes axonal growth impairment in motor neurons with TARDBP mutations. <i>Stem Cell Reports<\/i>, 16, 1527-1541. https:\/\/doi.org\/10.1016\/j.stemcr.2021.04.021","DOI":"10.1016\/j.stemcr.2021.04.021"},{"key":"51","doi-asserted-by":"publisher","unstructured":"Morimoto, S., Takahashi, S., Ito, D., Date, Y., Okada, K., Kato, C., Nakamura, S., Ozawa, F., Chyi, C.M., Nishiyama, A., Suzuki, N., Fujimori, K., Kondo, T., Takao, M., Hirai, M., et al. (2023)  Phase 1\/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. <i>Cell Stem Cell<\/i>, 30, 766-780e769. https:\/\/doi.org\/10.1016\/j.stem.2023.04.017","DOI":"10.1016\/j.stem.2023.04.017"},{"key":"52","doi-asserted-by":"publisher","unstructured":"Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., McCluskey, L.F., Miller, B.L., Masliah, E., Mackenzie, I.R., Feldman, H., et al. (2006)  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Science<\/i>, 314, 130-133. https:\/\/doi.org\/10.1126\/science.1134108","DOI":"10.1126\/science.1134108"},{"key":"53","doi-asserted-by":"publisher","unstructured":"Nishiyama, A., Niihori, T., Suzuki, N., Izumi, R., Akiyama, T., Kato, M., Funayama, R., Nakayama, K., Warita, H., Aoki, Y.&amp;Aoki, M. (2024)  Updated Genetic Analysis of Japanese Familial ALS Patients Carrying SOD1 Variants Revealed Phenotypic Differences for Common Variants. <i>Neurol. Genet.<\/i>, 10, e200196. https:\/\/doi.org\/10.1212\/NXG.0000000000200196","DOI":"10.1212\/NXG.0000000000200196"},{"key":"54","doi-asserted-by":"publisher","unstructured":"Nishiyama, A., Niihori, T., Warita, H., Izumi, R., Akiyama, T., Kato, M., Suzuki, N., Aoki, Y.&amp;Aoki, M. (2017)  Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiol. Aging, 53, 194 e191-194 e198. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2017.01.004","DOI":"10.1016\/j.neurobiolaging.2017.01.004"},{"key":"55","doi-asserted-by":"publisher","unstructured":"Oki, R., Izumi, Y., Fujita, K., Miyamoto, R., Nodera, H., Sato, Y., Sakaguchi, S., Nokihara, H., Kanai, K., Tsunemi, T., Hattori, N., Hatanaka, Y., Sonoo, M., Atsuta, N., Sobue, G., et al. (2022)  Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. <i>JAMA Neurol.<\/i>, 79, 575-583. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0901","DOI":"10.1001\/jamaneurol.2022.0901"},{"key":"56","doi-asserted-by":"publisher","unstructured":"Paganoni, S., Berry, J.D., Quintana, M., Macklin, E., Saville, B.R., Detry, M.A., Chase, M., Sherman, A.V., Yu, H., Drake, K., Andrews, J., Shefner, J., Chibnik, L.B., Vestrucci, M., Cudkowicz, M.E., et al. (2022)  Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. <i>Ann. Neurol.<\/i>, 91, 165-175. https:\/\/doi.org\/10.1002\/ana.26285","DOI":"10.1002\/ana.26285"},{"key":"57","doi-asserted-by":"publisher","unstructured":"Petrov, D., Mansfield, C., Moussy, A.&amp;Hermine, O. (2017)  ALS Clinical Trials Review: 20 Years of Failure. <i>Are We Any Closer to Registering a New Treatment?. Front. Aging Neurosci.<\/i>, 9, 68. https:\/\/doi.org\/10.3389\/fnagi.2017.00068","DOI":"10.3389\/fnagi.2017.00068"},{"key":"58","doi-asserted-by":"publisher","unstructured":"Quintana, M., Saville, B.R., Vestrucci, M., Detry, M.A., Chibnik, L., Shefner, J., Berry, J.D., Chase, M., Andrews, J., Sherman, A.V., Yu, H., Drake, K., Cudkowicz, M., Paganoni, S., Macklin, E.A., et al. (2023)  Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis. <i>Ann. Neurol.<\/i>, 94, 547-560. https:\/\/doi.org\/10.1002\/ana.26714","DOI":"10.1002\/ana.26714"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., Kalimo, H., Paetau, A., Abramzon, Y., Remes, A.M., Kaganovich, A., et al. (2011)  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. <i>Neuron<\/i>, 72, 257-268. https:\/\/doi.org\/10.1016\/j.neuron.2011.09.010","DOI":"10.1016\/j.neuron.2011.09.010"},{"key":"60","doi-asserted-by":"publisher","unstructured":"Rodriguez, C.M., Bechek, S.C., Jones, G.L., Nakayama, L., Akiyama, T., Kim, G., Solow-Cordero, D.E., Strittmatter, S.M.&amp;Gitler, A.D. (2022)  Targeting RTN4\/NoGo-Receptor reduces levels of ALS protein ataxin-2. <i>Cell Rep.<\/i>, 41, 111505. https:\/\/doi.org\/10.1016\/j.celrep.2022.111505","DOI":"10.1016\/j.celrep.2022.111505"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Rosen, D.R., Siddique, T., Patterson, D., Figlewicz, D.A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O&apos;Regan, J.P., Deng, H.X.&amp; et al. (1993)  Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.  <i>Nature<\/i>, 362, 59-62. https:\/\/doi.org\/10.1038\/362059a0","DOI":"10.1038\/364362c0"},{"key":"62","doi-asserted-by":"publisher","unstructured":"Sareen, D., O\u2019Rourke, J.G., Meera, P., Muhammad, A.K.M.G., Grant, S., Simpkinson, M., Bell, S., Carmona, S., Ornelas, L., Sahabian, A., Gendron, T., Petrucelli, L., Baughn, M., Ravits, J., Harms, M.B., et al. (2013)  Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. <i>Sci. Transl. Med.<\/i>, 5, 208ra149. https:\/\/doi.org\/10.1126\/scitranslmed.3007529","DOI":"10.1126\/scitranslmed.3007529"},{"key":"63","doi-asserted-by":"publisher","unstructured":"Seddighi, S., Qi, Y.A., Brown, A.L., Wilkins, O.G., Bereda, C., Belair, C., Zhang, Y.J., Prudencio, M., Keuss, M.J., Khandeshi, A., Pickles, S., Kargbo-Hill, S.E., Hawrot, J., Ramos, D.M., Yuan, H., et al. (2024)  Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS\/FTD. <i>Sci. Transl. Med.<\/i>, 16, eadg7162. https:\/\/doi.org\/10.1126\/scitranslmed.adg7162","DOI":"10.1126\/scitranslmed.adg7162"},{"key":"64","doi-asserted-by":"publisher","unstructured":"Shefner, J.M., Oskarsson, B., Macklin, E.A., Chibnik, L.B., Quintana, M., Saville, B.R., Detry, M.A., Vestrucci, M., Marion, J., McGlothlin, A., Heiman-Patterson, T., Chase, M., Pothier, L., Harkey, B.A., Yu, H., et al.; Writing Committee for the HEALEY ALS Platform Trial (2025) Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. <i>JAMA<\/i>, 333, 1128-1137. https:\/\/doi.org\/10.1001\/jama.2024.26429","DOI":"10.1001\/jama.2024.26429"},{"key":"65","doi-asserted-by":"publisher","unstructured":"Shneider, N.A., Harms, M.B., Korobeynikov, V.A., Rifai, O.M., Hoover, B.N., Harrington, E.A., Aziz-Zaman, S., Singleton, J., Jamil, A., Madan, V.R., Lee, I., Andrews, J.A., Smiley, R.M., Alam, M.M., Black, L.E., et al. (2025)  Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series. <i>Lancet<\/i>, 405, 2075-2086. https:\/\/doi.org\/10.1016\/S0140-6736(25)00513-6","DOI":"10.1016\/S0140-6736(25)00513-6"},{"key":"66","doi-asserted-by":"publisher","unstructured":"Suzuki, N., Nishiyama, A., Ebihara, S.&amp;Aoki, M. (2025)  Jacifusen for FUS-ALS: molecular effects and clinical outcomes in a case series. <i>Lancet<\/i>, 405, 2028-2030. https:\/\/doi.org\/10.1016\/S0140-6736(25)01038-4","DOI":"10.1016\/S0140-6736(25)01038-4"},{"key":"67","doi-asserted-by":"publisher","unstructured":"Takahashi, K., Kato, C., Ueda, K., Nakamura, S., Ozawa, F., Moritoki, N., Shibata, S., Takahashi, S., Morimoto, S.&amp;Okano, H. (2026)  Diagnostic potential of cryptic exon-derived peptides in serum extracellular vesicles for sporadic amyotrophic lateral sclerosis. <i>Inflamm. Regen.<\/i>, 46, 8. https:\/\/doi.org\/10.1186\/s41232-026-00404-w","DOI":"10.1186\/s41232-026-00404-w"},{"key":"68","doi-asserted-by":"publisher","unstructured":"Taylor, J.P., Brown, R.H. Jr . &amp; Cleveland, D.W.(2016)  Decoding ALS: from genes to mechanism. <i>Nature<\/i>, 539, 197-206. https:\/\/doi.org\/10.1038\/nature20413","DOI":"10.1038\/nature20413"},{"key":"69","doi-asserted-by":"publisher","unstructured":"Theunissen, F., Flynn, L., Iacoangeli, A., Al Khleifat, A., Al-Chalabi, A., Giordano, J.J., Stromme, M.&amp;Akkari, P.A. (2025)  Entering the era of precision medicine to treat amyotrophic lateral sclerosis. <i>Mol. Neurodegener.<\/i>, 20, 111. https:\/\/doi.org\/10.1186\/s13024-025-00890-5","DOI":"10.1186\/s13024-025-00890-5"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Tziortzouda, P., Van Den Bosch, L.&amp;Hirth, F. (2021)  Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. <i>Nat. Rev. Neurosci.<\/i>, 22, 197-208. https:\/\/doi.org\/10.1038\/s41583-021-00431-1","DOI":"10.1038\/s41583-021-00431-1"},{"key":"71","doi-asserted-by":"publisher","unstructured":"van den Berg, L.H., Rothstein, J.D., Shaw, P.J., Babu, S., Benatar, M., Bucelli, R.C., Genge, A., Glass, J.D., Hardiman, O., Libri, V., Mobach, T., Oskarsson, B., Pattee, G.L., Ravits, J., Shaw, C.E., et al. (2024)  Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. <i>Lancet Neurol.<\/i>, 23, 901-912. https:\/\/doi.org\/10.1016\/S1474-4422(24)00216-3","DOI":"10.1016\/S1474-4422(24)00216-3"},{"key":"72","doi-asserted-by":"publisher","unstructured":"van Rheenen, W., van der Spek, R.A.A., Bakker, M.K., van Vugt, J., Hop, P.J., Zwamborn, R.A.J., de Klein, N., Westra, H.J., Bakker, O.B., Deelen, P., Shireby, G., Hannon, E., Moisse, M., Baird, D., Restuadi, R., et al. (2021)  Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nat. Genet.<\/i>, 53, 1636-1648. https:\/\/doi.org\/10.1038\/s41588-021-00973-1","DOI":"10.1038\/s41588-021-00973-1"},{"key":"73","doi-asserted-by":"publisher","unstructured":"Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K.L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., et al. (2009)  Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. <i>Science<\/i>, 323, 1208-1211. https:\/\/doi.org\/10.1126\/science.1165942","DOI":"10.1126\/science.1165942"},{"key":"74","doi-asserted-by":"publisher","unstructured":"Warita, H., Kato, M., Asada, R., Yamashita, A., Hayata, D., Adachi, K.&amp;Aoki, M. (2019)  Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP-100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial. <i>J. Clin. Pharmacol.<\/i>, 59, 677-687. https:\/\/doi.org\/10.1002\/jcph.1355","DOI":"10.1002\/jcph.1355"},{"key":"75","doi-asserted-by":"publisher","unstructured":"Wilkins, O.G., Chien, M., Wlaschin, J.J., Barattucci, S., Harley, P., Mattedi, F., Mehta, P.R., Pisliakova, M., Ryadnov, E., Keuss, M.J., Thompson, D., Digby, H., Knez, L., Simkin, R.L., Diaz, J.A., et al. (2024)  Creation of de novo cryptic splicing for ALS and FTD precision medicine. <i>Science<\/i>, 386, 61-69. https:\/\/doi.org\/10.1126\/science.adk2539","DOI":"10.1126\/science.adk2539"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/4\/269_2026.J082\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:35:36Z","timestamp":1789788936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/269\/4\/269_2026.J082\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.2026.j082","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.J082"}}